Page 3 - Read Online

Determining an optimal nomenclature for MFLS presents challenges. Ideally, such
terminology should be easily intelligible for most people and support precision medicine
approaches by enabling the classification of homogeneous patient subgroups with similar
disease trajectories. Equally important, it should gain consensus among stakeholders,
including patients, physicians, nurses, healthcare providers, policymakers, researchers,
clinicians, and representatives from industries involved in drug development and the
manufacture of diagnostic tools and medical devices.

Scientific progress relies on the continuous generation and critical analysis of new
data, and the definition of MFLS nomenclature is no exception. The capacity of each
proposed term to pinpoint specific patient populations and delineate diverse disease
trajectories warrants rigorous empirical evaluation to weigh their merits and drawbacks.

Within this rapidly evolving scenario, the present Special Issue welcomes a broad
spectrum of contributions, including Letters to the Editor, Editorials, Commentaries,
Perspectives, Original Research Articles, and Review Articles, addressing the various
nomenclatures of MFLS - namely NAFLD/NASH and MAFLD/MASLD. Submissions
examining stigma associated with MFLS are also welcomed.